GET DAILY SIGNALSPDS Biotechnology (PDSB) Q3 2026 Earnings Preview: Narrowing Losses and Clinical Milestones in Focus
Key Takeaways
- PDS Biotechnology Corporation (PDSB) is expected to report third-quarter 2026 results on November 12, 2026, before the market opens.
- Wall Street consensus calls for a net loss of $0.11 per share, narrower than the $0.19 per-share loss reported in the same quarter a year earlier.
- As a clinical-stage biotech, PDS Biotech generates no product revenue, so investors will focus on cash levels, spending trends, and clinical milestones rather than sales.
- The company recently secured up to $22.55 million in financing led by Nant Capital, strengthening its balance sheet ahead of key readouts.
- Updates on the Phase 3 VERSATILE-003 trial of PDS0101 and the PDS01ADC program are likely to drive the market's reaction more than the headline loss.
- In its most recent report, the company posted a loss of $0.18 per share, missing the $0.13 consensus estimate — a reminder that estimates can shift quickly.
Earnings Context and Why It Matters
PDS Biotechnology Corporation is a late-stage immuno-oncology company working to transform how the immune system targets and kills cancers. Because it has not yet brought a product to market, its quarterly reports carry no revenue — meaning the traditional earnings framework does not fully apply. Instead, investors read these updates for signals about cash runway, operating expense discipline, and clinical progress. The company's lead candidate, PDSB, is advancing through the Phase 3 VERSATILE-003 trial for HPV16-positive head and neck cancer, while PDS01ADC is being studied in colorectal and prostate cancers. With a recent financing round and an amended trial protocol aimed at accelerating potential approval, this report is a key checkpoint for evaluating the company's path forward.
Earnings Expectations
Analysts expect PDSB to report a third-quarter 2026 loss of $0.11 per share (EPS, or earnings per share), based on a small pool of estimates that ranges from a loss of $0.10 to $0.11. That would represent meaningful improvement from the $0.19 per-share loss reported in the third quarter of 2025. Revenue is expected to be zero, reflecting the company's pre-commercial stage.
Historical results provide useful context. In the first quarter of 2026, PDSB posted a loss of $0.13 per share, beating the $0.15 consensus estimate. However, in the second quarter of 2026, the company reported a loss of $0.18 per share, missing the $0.13 consensus. Investors will therefore watch closely whether the company can return to its earlier trend of narrowing losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Beyond the headline EPS figure, key metrics to monitor include the cash balance, research and development (R&D) expenses, and general and administrative (G&A) costs, as well as any updates on patient enrollment and data timelines for the VERSATILE-003 trial.
Market Reaction and Investor Sentiment
Sentiment heading into the third-quarter report is shaped less by near-term earnings and more by the company's clinical and financing milestones. The recent $22.55 million private investment in public equity (PIPE) transaction led by Nant Capital, which brought Dr. Patrick Soon-Shiong onto the board, was seen as an important vote of confidence and a means to extend the company's cash runway. That news helped stabilize the stock after a challenging period.
At the same time, PDSB carries a relatively modest cash position and continues to post losses, leaving it sensitive to execution risk and the potential for further dilution. The stock's last earnings reaction underscored this volatility, as the second-quarter miss weighed on shares. Investors will be looking for concrete evidence that cost discipline is holding and that the amended VERSATILE-003 protocol is keeping the program on a faster, more efficient path. From what I see, clinical updates will likely outweigh the EPS number itself.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important catalysts for PDSB are clinical rather than financial. The company amended the VERSATILE-003 protocol to add progression-free survival (PFS) — the length of time a patient lives without the disease worsening — as an interim co-primary endpoint while retaining overall survival (OS) for full approval. This change, aligned with the U.S. Food and Drug Administration (FDA), is intended to enable a potential accelerated approval pathway.
Investors should also track the PDS01ADC program, where a colorectal cancer cohort is fully enrolled and additional data are expected around year-end. This antibody-drug conjugate (ADC), which incorporates an immune-stimulating molecule, represents a second potential avenue for long-term value.
Financially, the focus will remain on whether the company can keep operating expenses manageable and whether its cash position, supplemented by the recent PIPE financing and a possible milestone-linked second closing, provides sufficient runway to reach the next major data readouts. Patent protection extending into the 2040s offers another supportive element.
As with any clinical-stage oncology company, results remain subject to trial outcomes, regulatory decisions, and financing needs, and investors should weigh these factors carefully rather than relying on any single quarter's figures.
Using Tickeron’s AI Screener for Deeper Biotech Insights
In my own research process, Tickeron’s AI Screener has become a practical way to quickly filter biotech names by fundamentals, technical patterns, and AI-driven signals. It helps surface comparable companies and spot trends that might otherwise take hours to identify manually. For someone following names like PDSB, this kind of tool adds structure to the screening workflow without replacing careful fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PDSB's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 21 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In 74 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PDSB moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for PDSB moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +19.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 80 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.902) is normal, around the industry mean (3.498). P/E Ratio (-1.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement